ConductScience.org, home

Comparison · NCT04308668-55245cee

Treatment vs Placebo: Rate of Death

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Treatment vs Placebo: Rate of Death. Trial comparisons, record NCT04308668-55245cee. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04308668-55245cee

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.001550.0002740.00873wilson
Risk in group 20.001560.0002750.00878wilson
Risk difference, group 1 minus group 2-0.00000967-0.007340.00728newcombe hybrid score
Risk ratio, group 1 over group 20.9940.062315.9log
Odds ratio, group 1 over group 20.9940.06215.9log
Number needed to treat, for one fewer participant with the outcome on Treatment than on Placebo103,000from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1TreatmentParticipants in this arm will receive the study drug.~Hydroxychloroquine: 200mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600mg once a day for 4 consecutive days1645OG000
Group 2PlaceboParticipants in this arm will receive a placebo treatment.~Placebo: 4 placebo tablets once, followed in 6 to 8 hours by 3 tablets, then 3 tablets once-a-day for 4 consecutive days1641OG001

Outcome

Type
SECONDARY
Title
Rate of Death
Description
Outcome reported as the number of participants in each arm who expire due to COVID-19-related disease through study completion of 14 days. For those hospitalized within the 14-day study period, the protocol specified follow up would occur for up to 90 days to capture the final outcome of participants' hospitalization. Approximately 30-days was the maximal follow up for hospitalization outcome needed in the trial.
Time frame
Approximately 30 days
Population

Source ClinicalTrials.gov

Trial

Title
Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
NCT number
NCT04308668
Phases
PHASE3
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus, Coronavirus Infections
Interventions
Hydroxychloroquine, Placebo
Lead sponsor
University of Minnesota
Results first posted
2021-05-13

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04308668-55245cee